With 0.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 57210.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.8 whereas the lowest price it dropped to was $8.72. The 52-week range on AVTX shows that it touched its highest point at $34.46 and its lowest point at $3.95 during that stretch. It currently has a 1-year price target of $33.00. Beta for the stock currently stands at 0.89.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVTX was down-trending over the past week, with a drop of -3.47%, but this was down by -18.26% over a month. Three-month performance dropped to -7.86% while six-month performance fell -33.66%. The stock lost -13.66% in the past year, while it has lost -2.09% so far this year. A look at the trailing 12-month EPS for AVTX yields -168.23 with Next year EPS estimates of -5.31. For the next quarter, that number is -1.42. This implies an EPS growth rate of 77.38% for this year and 79.42% for next year.
Float and Shares Shorts:
At present, 9.68 million AVTX shares are outstanding with a float of 8.40 million shares on hand for trading. On 2024-11-29, short shares totaled 5218.0, which was 5.0 higher than short shares on 1730332800. In addition to Dr. Garry A. Neil M.D. as the firm’s Chairman of the Board, President & CEO, Mr. Christopher Ryan Sullivan CPA serves as its CFO & Head of Investor relations.
Institutional Ownership:
Through their ownership of 0.64989 of AVTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AVTX reported revenue of $249000.0 and operating income of -$12861000.0. The EBITDA in the recently reported quarter was -$47752000.0 and diluted EPS was -$2.83.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVTX since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AVTX analysts setting a high price target of 40.0 and a low target of 35.0, the average target price over the next 12 months is 37.5. Based on these targets, AVTX could surge 348.93% to reach the target high and rise by 292.82% to reach the target low. Reaching the average price target will result in a growth of 320.88% from current levels.
Analysts have provided yearly estimates in a range of -$2.21791 being high and -$49.34856 being low. For AVTX, this leads to a yearly average estimate of -$25.79.
